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Abstract
Introduction
The gene encoding isocitrate dehydrogenase 1 (IDH1) is frequently mutated in several
tumor types including gliomas. The most prevalent mutation in gliomas is a missense muta-
tion leading to a substitution of arginine with histidine at the residue 132 (R132H). Wild type
IDH1 catalyzes oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) whereas
mutant IDH1 converts α-KG into D2-hydroxyglutarate (D2HG). Unfortunately, there are few
in vivo model systems for IDH-mutated tumors to study the effects of IDH1 mutations in
tumor development. We have therefore created transgenic zebrafish lines that express vari-
ous IDH1 mutants.
Materials and methods
IDH1 mutations (IDH1R132H, IDH1R132C and loss-of-function mutation IDH1G70D), IDH1wildtype
or eGFP were cloned into constructs with several brain-specific promoters (Nestin, Gfap or
Gata2). These constructs were injected into fertilized zebrafish eggs at the one-cell stage.
Results
In total more than ten transgenic zebrafish lines expressing various brain-specific IDH1
mutations were created. A significant increase in the level of D2HG was observed in all
transgenic lines expressing IDH1R132C or IDH1R132H, but not in any of the lines expressing
IDH1wildtype, IDH1G70D or eGFP. No differences in 5-hydroxymethyl cytosine and mature col-
lagen IV levels were observed between wildtype and mutant IDH1 transgenic fish. To our
surprise, we failed to identify any strong phenotype, despite increased levels of the oncome-
tabolite D2HG. No tumors were observed, even when backcrossing with tp53-mutant fish
which suggests that additional transforming events are required for tumor formation. Ele-
vated D2HG levels could be lowered by treatment of the transgenic zebrafish with an inhibi-
tor of mutant IDH1 activity.
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Conclusions
We have generated a transgenic zebrafish model system for mutations in IDH1 that can be
used for functional analysis and drug screening. Our model systems help understand the
biology of IDH1 mutations and its role in tumor formation.
Introduction
Somatic missense mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) or IDH2
are frequently identified in various malignancies including gliomas, acute myeloid leukemia,
cholangiocarcinoma, chondrosarcoma and sporadically in various other cancer types [1–8]. In
gliomas, IDH1 mutations are one of the earliest genetic changes identified, preceding other
common genetic aberrations such as 1p19q co-deletion, and are therefore present in virtually
all tumor cells [9–11]. IDH1 and IDH2 mutations are almost always mutually exclusive. For gli-
oma patients, presence of IDH mutations is of clinical relevance as patients harboring IDH
mutated gliomas have a better survival compared to those with wildtype IDH. The prognostic
significance of IDH mutations has led to its incorporation in the WHO 2016 update to classify
gliomas [12]. Mutations in IDH1 are almost always heterozygous point mutations affecting
the arginine at position 132 (R132). Approximately 90% of these mutations in gliomas are
IDH1R132H.
Wildtype IDH1 is a cytoplasmic enzyme that catalyzes the oxidative decarboxylation of iso-
citrate to α-ketoglutarate (αKG) and uses NADP+ as a co-factor [13, 14]. The mutant enzyme
however, uses αKG as a substrate to produce D-2-hydroxyglutarate (D2HG) with concomitant
consumption of NADPH [15]. The resulting accumulation of D2HG then competitively inhib-
its a spectrum of αKG-dependent enzymes including TET2, JMJD2 and various prolyl hydrox-
ylases [16–18]. This inhibition ultimately facilitates carcinogenesis by retaining cells in an
undifferentiated and stem-like state. Because of the oncogenic role of mutant IDH1, several
groups have developed compounds that specifically inhibit the activity of the mutant enzyme
[19, 20]. These inhibitors are currently being tested in clinical trials.
Several IDH1R132H conditional knock-in (KI) mouse models were recently generated to fur-
ther study the role of the mutant enzyme in an in vivo model system. Unfortunately most mice
in which IDH1 mutations were conditionally expressed either died before birth or rapidly
after induction of expression of the mutant enzyme [21]. Nevertheless, expression of mutant
IDH1 results in a retention of cells in an undifferentiated state or induces pre-cancerous
lesions in cartilage or the SVZ [22–24]. Despite these signs of early tumor formation, no glio-
mas in any of the three mouse models were thus-far identified, also not when backcrossing
into a Tp53 -mutant background [23, 25].
To further study the effects of IDH1 mutations in tumor development, we have generated
transgenic zebrafish that express IDH1 mutants under the control of various CNS-specific
promoters.
Materials and methods
Cloning
Human pEGFP-IDH1wildtype and pEGFP-IDH1R132H constructs were described as previous
[26]. IDH1R132C and IDH1G70D mutations were cloned by in-fusion PCR with two sets of prim-
ers, 5’-CTATCATCATAGGTTGTCATGCTTATGGGGATCAATAC-3’ and 5’-CCATAAGCA
TGACAACCTATGATGATAGGTTTTAC-3’ for IDH1R132C; 5’-AGAAGCATAATGTTGACGT
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CAAATGTGCCAC-3’ and 5’-GTGGCACATTTGACGTCAACATTATGCTTCT-3’ for
IDH1G70D. The whole construct was linearized and inserted into a miniTol2 vector (Addgene,
plasmid #31829).
Generation of transgenic zebrafish
All experiments with zebrafish (Tupfel long fin or TL) were conducted according to the proto-
cols approved by the Animal Experimentation Committee of the Erasmus Medical center
and EU guidelines. To generate transgenic zebrafish lines expressing GFP-IDH1wildtype and
GFP-IDH1R132H driven by different promoters (Nestin, Gata2 and Gfap), we injected various
constructs into the cells of fertilized zebrafish eggs at the one-cell stage. Embryos that showed
GFP expression at 1 day post fertilization (dpf) were collected and raised to adulthood (3
months, F0) and then individually crossed with non-transgenic wildtype TL (F1). GFP expres-
sion in the F1 fish indicated that the constructs were integrated into the fish genome. The
GFP-positive F1s were separately raised to adults and then interbred to generate homozygous
F2. Although we did not actually test for homozygosity of our transgenic lines, we inferred this
by the observation that all F2 inbred offspring expressed GFP. All F2 progenies were further
inbred. The experiments were performed mainly on likely homozygous F4 zebrafish. tp53
mutant fish (tp53M214K) were described by Berghmans et al and obtained from ZFIN (ZFIN.
org) [27].
Histology and Immunohistochemistry
Zebrafish embryos were fixed overnight in 4% paraformaldehyde (PFA) at 4˚C and then
embedded in paraffin for further histological analysis. Paraffin sections (6 μm) were stained
with hematoxylin and eosin (HE). For immunohistochemistry (IHC), paraffin sections were
dewaxed and hydrated followed by boiling in 10 mM sodium citrate for eight minutes and 2
times 3 minutes of boiling in a microwave oven. Prior to immunostaining, the endogenous
peroxidase activity was blocked by 30% hydrogen peroxide and 12.5% sodiumazide in PBS for
30 minutes. The slides were washed in PBS and PBS+ which contained 0.5% g/ml protifar and
0.15% g/ml glycine and then incubated with primary antibody overnight at 4˚C. The primary
antibodies used were anti-GFP (1:2000) monoclonal antibody (Roche, Woerden, the Nether-
lands), 5hmC (1: 200, Active Motif, La Hulpe, Belgium) and anti-human IDH1R132H (1:200)
monoclonal antibody (Dianova, clone DIA H09, Huissen, the Netherlands), diluted in PBS+.
The sections were then washed in PBS+ and incubated with BrightVision Poly-HRP-Anti IgG
(immunologic) for 60 minutes at room temperature (RT). The slides were washed in PBS
+ and PBS and then treated with 1:50 diluted DAB-substrate (DAKO Liquid DAB substrate-
chromogen system) for 4–8 minutes, followed by counterstaining with haematoxylin and
mounted in entellan. Histological images were captured using an Olympus BX40 camera.
Real-time PCR
To examine the expression of IDH1 and GFP during envelopment, total RNA was extracted by
dissolving embryos in 500 μl TRIzol1 (Life technologies, Carlsbad, USA) and 100 μl chloro-
form followed by centrifugation at 12.000 g for 15 min at 4˚C. RNA in the aqueous phase was
precipitated with 250 μl isopropanol and collected at 12 000 g for 10 minutes at 4˚C. The pellet
was washed twice in 250 μl 75% ethanol, centrifuged at 12 000 g for 5 minutes at 4˚C, dried
and dissolved in 10 μl nuclease free water (Ambion, Thermo Scientific, Rochester, USA). For
cDNA synthesis, each reaction contained 1000 ng RNA, 1 μl hexamers, 1 μl 10 mM dNTP’s
and milliQ water to 13 μl and was heated to 65˚C for 5 minutes and left on ice for at least 1
minute. The RNA was then treated with 4 μl 5x Firststrand buffer, 1 μl 0.1M DTT, 0.5 μl
A transgenic zebrafish model for mutations in IDH1
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RNaseOUT and 0.5 μl DNase. The samples were heated to 37˚C for 40 minutes and further
heated to 65˚C for 10 minutes. The RNAs were then reverse-transcribed by adding 1 μl Super-
script III (Invitrogen, Breda, the Netherlands) and 0.5 μl RNase OUT followed by incubation
at 25˚C for 5 minutes and 42˚C for one hour. 1 μl cDNA was used in a 15 μl reaction contain-
ing 7.5 μl Syber Select Mastermix (Life technologies), 1mM primers and MilliQ. The primer
sequences are described in S1 Table. The reactions were performed in triplicate using a CFX96
Real-Time PCR System (Bio-Rad). The threshold cycle (Cq) for each reaction was obtained
and the values were averaged. The standard deviation (SD) had to be below 0.2. The relative
expression levels, of different time points in zebrafish life, were calculated. First the ΔCq of a
sample was calculated; ΔCq = IDH1 Cq mean- β-actin Cq mean. Then one time point was set
as a reference (= 1.00) and the ΔΔCq was calculated as ΔΔCq = ΔCq reference—ΔCq unknown
sample. To calculate the relative expression levels the formula 2^ ΔΔCq was used.
Protein extraction and immunoblotting
Zebrafish embryos were lysed in 500 μl HEPES-buffer containing 1x protease inhibitor (cOm-
plete, Thermo Scientific) and 3 μM DTT followed by homogenization by a PRO 200 homoge-
nizer and incubated on ice for 30 minutes. 50 μg of protein was separated by loading onto a
precast SDS gel (Thermo Scientific) and electrophoresis at 150 V till loading buffer reached the
bottom of the gel. Protein was then transferred to a nitrocellulose membrane in transfer buffer
at 100 V, 380 mA, for 1 hour. The membrane was blocked with blocking buffer containing 1%
BSA in PBS for 1 hour at room temperature and incubated with primary antibody overnight at
4˚C with agitation. Primary antibodies used were anti-Collagen Type IV (1:1000, Abcam, Hil-
versum, The Netherlands) and 5hmC (1: 1000).
Microinjection of wildtype zebrafish embryos with Gfap constructs
20 μl of injection solution containing 350 ng of Gfap constructs, 30 ng/μl Tol2 transposase
RNA and 0.1% pheno-red was freshly prepared before injection. 4.2 nl of injection solution
was injected into the cell of 1-cell stage embryos using a Pneumatic PicoPump (PV820, WPI).
For each construct, injection was performed on 100 eggs in three independent experiments.
The fertilization rate was calculated based on 30 uninjected embryos collected on the same
day. The number of GFP+, GFP-, healthy and abnormal embryos were counted on 1dpf.
5hmC assay
Total DNA was extracted using whole fish embryos. A nitrocellulose membrane was pre-
soaked in 20X SSC for 1 hour. 250 ng DNA was diluted in 150μl H2O and 150μl 20X SSC. The
membrane and two layers of thick filter papers were placed on a manifold (manifold II slot-
blot manifold, Cole-Parmer, Wertheim, Germany) and equilibrated with 10X SSC. DNA sam-
ples were then loaded and fixed on the membrane using a vacuum pump for 5 minutes. The
membrane was air-dried and processed as described above in the immunoblotting section.
Blots were stained using the 5hmC antibody (1:1000) and analyzed using ECL.
IDH1 mutant inhibitor test
Five transgenic zebrafish embryos from each line were screened for GFP expression at 1 or 2
dpf and removed from the chorion and raised in 2 ml tap water for 48 hours with either 10μM
AGI-5198 (Xcess Biosciences, Inc.) in 0.1% DMSO or 0.1% DMSO. Zebrafish embryos were
collected at 3 dpf in 25 μl of HBSS buffer for 2HG measurement.
A transgenic zebrafish model for mutations in IDH1
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Quantification of D/L2HG in zebrafish
To quantify the level of D- and L2HG in the zebrafish, five embryos were collected at 1, 2, 3, 5
and 6 dpf in HBSS buffer (5μl per embryo). The embryos were homogenized with a PRO 200
homogenizer and lysed with sonication before LC-MS/MS. The D and L forms of 2HG were
separately measured and quantified as described previously [28].
Statistics
Differences in D- and L- 2HG levels between experimental conditions were evaluated using
the students t-test. A Fisher’s exact test was used to compare differences between frequencies.
Results
Generation and characterization of transgenic zebrafish lines
We firstly generated transgenic lines for two constructs, eGFP-IDH1wildtype and eGF-
P-IDH1R132H, in which the transgene was expressed under control of a Nestin promoter. These
constructs are referred to as NesIDH1wt and NesR132H. At least two independent lines per con-
struct were generated to control for integration-site dependent effects.
Transgene expression was detected in the brain and spinal cord on 1, 3 and 6 days post fertili-
zation (dpf) by fluorescent imaging (Fig 1A and S1A Fig) and by immunohistochemistry (Fig 1B)
using anti-GFP antibodies. Expression of NesR132H was confirmed using an IDH1R132H-mutant
specific antibody (S2 Fig). As expected, this antibody did not show staining in the NesIDH1wt-fish.
Expression of transgenes on 1, 2, 3 and 6 dpf was also detected on the RNA level by RT-QPCR
(Fig 1C). We then measured D2HG levels to monitor the activity of the neomorphic enzyme.
Consistent with RNA and protein expression, the D2HG level in NesR132H mutant transgenic fish
was elevated compared to controls (non-transgenic and NesIDH1wt) on 1–5 dpf (Fig 1D). The
increase in D2HG was virtually identical when using macro-dissected embryos (head region)
compared to whole fish (S3 Fig). L2HG levels in all the transgenic lines were similar to the non-
transgenic controls (Fig 1E); indicating expression of IDH1R132H only affects D2HG levels. D2HG
levels returned to normal by 21 dpf. These experiments demonstrate CNS-specific expression of
IDH1wt or IDH1R132H in our transgenic zebrafish lines during development. This temporal expres-
sion pattern in the CNS is consistent with the Nestin promoter activity [29–31].
It has been reported that accumulation of D2HG results in DNA hypermethylation by inhi-
bition of TET enzymes [32]. In our transgenic fish, DNA methylation as determined by 5hmC
antibody staining was however not affected (S4 Fig). We next screened for collagen maturation
defects, as these were observed in an IDH1R132H-KI mouse model [21]. However, western blot
analysis failed to detect the presence of immature isoforms of collagen in our transgenic fish
lines (S5 Fig). In summary, despite expression of the transgene (and the elevated levels of
D2HG in lines expressing NesR132H), all of the zebrafish lines remained healthy without pre-
senting any identifiable developmental abnormalities (S6 Fig).
Given the short temporal expression of IDH1 constructs driven by the Nestin promoter, we
cloned constructs under the control of a brain specific Gata2 promoter. This promoter was
previously used for constructing a transgenic zebrafish model for neurodegeneration [33].
Three transgenic lines were generated, pGata2-GFP-IDH1wt, pGata2-GFP-IDH1R132H and pGa-
ta2-GFP. These constructs are referred to as GataIDH1wt, GataR132H and GataGFP. Unfortu-
nately, we failed to observe any transgene expression in the developing (or adult) CNS in any
of the lines generated. We did however observe expression in the notochord from 1 for up to 5
dpf (S7 Fig), but, despite expression of a D2HG-producing IDH1 mutant, all fish were viable,
developed normally and produced offspring. Similar to the NesIDH1wt and NesR132H fish, no
A transgenic zebrafish model for mutations in IDH1
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gross abnormalities or (pre-) neoplastic lesions were observed. As we failed to observe expres-
sion in the CNS we did not further investigate these lines.
Because of the temporal limitations of the Nestin promoter and the lack of expression in the
CNS using the Gata2 promoter, we generated six additional lines, one for eGFP-IDH1wildtype,
eGFP-IDH1R132H, eGFP-IDH1G70D and eGFP, and two for eGFP-IDH1R132C, in which the trans-
gene was expressed under control of a Gfap promoter. Constructs used for these lines are
Fig 1. Characterization of NesIDH1 zebrafish lines. Expression of the transgene was detected in the central nervous system (CNS) of zebrafish embryos using
fluorescent imaging (A: non-transgenic wildtype zebrafish showing background auto-fluorescence staining, mainly in the yolk sac; A’: NesIDH1 show expression of the
transgene in the CNS of 3dpf embryos). Expression was confirmed by immunochemistry staining using an anti-GFP antibody (B) and Q-PCR (C). D2HG only
accumulated in NesR132H zebrafish (D, non-transgenic vs NesIDH1wt, p = 0.754, non-transgenic vs NesR132H, p = 0.003, student’s t-test). L2HG levels in the transgenic lines
showed no such increase (E). For Q-PCR experiments, we used a pool of five fish per time-point; D2HG and L2HG measurements were averages of two replicates using
5 fish per replicate. Scale bar: 200 μm.
https://doi.org/10.1371/journal.pone.0199737.g001
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referred to as GfapIDH1wt, GfapR132H, GfapR132C, GfapG70D and GfapGFP. The expression vector
(gfap:GFP) has been demonstrated to have glial-specific expression in the zebrafish CNS,
detectable during the embryonic stage [34]. The IDH1G70D mutation is an enzymatic null
mutation that was included to serve as a non-D2HG-producing control [15, 35]. The
IDH1R132C mutation was generated to study potential differences between IDH1R132H and
IDH1R132C, and is a mutant with reportedly higher neomorphic enzymatic activity [36].
Expression of the transgenes was confirmed using fluorescent imaging on 1, 3 and 5 dpf (Fig
2A and S1B Fig). GFP was observed in the brain and spinal cord in all the Gfap transgenic zeb-
rafish lines. CNS-specific expression of the transgene was further confirmed by immunohis-
tochemistry using anti-GFP antibodies (Fig 2B). Expression of the transgene on the RNA level
was confirmed by RT-QPCR till at least 20 dpf (Fig 2C). There were no obvious differences in
results from these assays between IDH1R132H and IDH1R132C transgenic zebrafish. The D2HG
levels were markedly elevated in both GfapR132C zebrafish lines (line 84 and 85) on 3 dpf,
which are about 8 and 18 times higher compared to the GfapGFP and GfapIDH1wt lines (line 73
and 92, Fig 2D). D2HG levels in GfapG70D zebrafish remained similar as in GfapGFP and Gfa-
pIDH1wt lines. L2HG levels of all the IDH1 transgenic lines were similar to the GfapGFP control,
confirming that expression of transgene only affects the D2HG level (Fig 2E).When crossing
GfapR132C line 85, an average of 21.1% of generated embryos showed abnormal tail develop-
ment on 1dpf, which was higher than in the GfapGFP (3%) and GfapIDH1wt (0%) control lines
(Fig 2F and 2G). The tail defects may be explained by the fact that the first detectable expres-
sion of Gfap is at 10 h post fertilization in the developing tail bud [34]. However, no clear
(pre-) cancerous lesion was observed in any of the zebrafish lines studies.
It is possible that IDH1R132H/R132C induced a pathologic phenotype due to the site of integra-
tion of our transgene. To correct for potential integration site artifacts, we directly injected fer-
tilized zebrafish eggs at the one-cell stage with various constructs and monitored zebrafish
development. We specifically monitored tail development in our transgenic fish. In three inde-
pendent experiments, we injected fertilized eggs with GfapGFP, GfapIDH1wt or GfapR132C con-
structs. While most embryos injected with GfapGFP remained healthy (n = 105/129, S8A and
S8D Fig), most embryos injected with the GfapR132C construct were not (n = 75/85, P<0.001,
Fisher’s exact test). In line with our transgenic lines, many showed an abnormal development
of the tail on 1dpf. However, zebrafish embryos injected with GfapIDH1wt constructs also some-
times had abnormal tail development, though the frequency was significantly lower than that
of GfapR132C (n = 13/24, P<0.001).
tp53 deficient Transgenic zebrafish crossed with IDH1 mutant fish
TP53 mutations often co-occur in IDH1-mutated astrocytomas. To determine whether
GfapR132C affects tumor formation, we crossed the homozygous tp53M214K mutant transgenic
zebrafish with our transgenic zebrafish lines. It was previously reported that homozygous
tp53 mutant zebrafish developed tumors (Schwannomas) at ~8 months post fertilization with
an incidence of 28% [27]. Although we find that heterozygous tp53 mutant fish developed
tumors (Table 1 and S9 Fig, incidence = 15%, n = 2/13) with an average age of onset ~1 year
post fertilization, this incidence was not increased when the fish were crossed into a pGfap:
GFP-IDH1R132H (or wt) background, with incidence between 6 to 14.3% regardless of the IDH1
variants or GFP controls (P>0.3 for all comparisons, Fisher’s exact test). The non-CNS tumors
we observe in our transgenic lines are most likely Schwannomas, as previously described [27].
They are mainly in the abdominal cavity, an area where we do not see expression of our trans-
gene. Our results therefore demonstrate that expression of mutant IDH1 does not promote
tumor formation in tp53 mutant zebrafish.
A transgenic zebrafish model for mutations in IDH1
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Fig 2. Characterization of Gfap zebrafish lines. Expression of transgene was detected using fluorescent imaging (A), immunohistochemistry
with an anti-GFP antibody (B) and QPCR (C). Elevated levels of D2HG were only detected in GfapR132C lines (D). L2HG levels in the transgenic
A transgenic zebrafish model for mutations in IDH1
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IDH1 mutated transgenic zebrafish as an in vivo model for drug screening
AGI-5198 is a specific inhibitor for the IDH1 mutant enzymatic activity [19]. To determine
whether this inhibitor also affects D2HG production in vivo, we applied it to our transgenic
zebrafish lines harboring different IDH1 variants under control of the Nestin and Gfap pro-
moters at 1dpf for 48 hours. Dose-response analysis indicates maximal inhibition at 10μM
AGI-5198 on the NesIDH1 transgenic zebrafish (S10 Fig). The inhibitor did not show any overt
toxicity, even after prolonged (2 days) treatment. The accumulated D2HG in our NesR132H
transgenic zebrafish was decreased by 10 μM AGI-5198 to 41% of the levels prior to treatment
whereas D2HG levels in the non-transgenic and NesIDH1wt transgenic zebrafish were not
affected (Fig 3A). The D2HG levels were also markedly reduced in the GfapR132C zebrafish line
from 34.86 reduced to 8.77 pmol (25% of the D2HG level in the untreated fish (Fig 3B)). Levels
of D2HG in control transgenic lines remained low and were not affected by the inhibitor. The
L2HG level in all of the treated transgenic lines was not altered (Fig 3C and 3D). These data
demonstrate that our transgenic zebrafish lines can be used to screen the efficacy and toxicity
of drugs that inhibit IDH1 mutant enzyme activity.
Discussion
Studying IDH1 mutations in gliomas has been hampered by the difficulty in generating appro-
priate model systems. For example, IDH-mutated gliomas are notoriously difficult to propa-
gate in vitro [37] and mouse models for IDH1 mutations often have a lethal phenotype when
IDH1R132H is expressed at early stages of development [21, 23, 25]. Mice can survive when the
mutant protein is expressed at later stages, but often with severe phenotypes (e.g. hydrocepha-
lus). A Drosophila model with UAS-Idh-R195H resulted in defects in wing expansion [38].
Here we report on transgenic zebrafish model systems for IDH1 mutations, and show that
expression of IDH1 mutations and subsequent accumulation of D2HG does not overtly affect
zebrafish development in the majority of offspring. However, tail development defects were
observed in a subset of offspring in one line and also following direct injection of mutant con-
structs in wildtype zebrafish embryos (S8 Fig). Expression of mutant, but not wildtype IDH1
may therefore affect the cells required for normal tail development.
In contrast to the Nestin or GFAP-R132H KI mouse models, we did not observe any overt
phenotype in any of the NesR132H transgenic zebrafish and the majority of Gfap transgenic fish.
In mice, the brain hemorrhage phenotype is caused by collagen maturation defects (caused by
inhibition of prolyl hydroxylases by D2HG) [21]. Alternatively, brain hemorrhages may be sec-
ondary to D2HG mediated coagulation defects [39]. In our transgenic lines, we failed to detect
fish embryos were not affected (E). About 21% GfapR132C embryos showed defects in tail development on 1dpf (F and G). Arrow heads: the site of
abnormal tail development in the GfapR132C embryos. For Q-PCR experiments, we used a pool of five (3dpf) or three (20 dpf) fish per time-point;
D2HG and L2HG measurements were averages of two replicates using five (3 and 5 dpf) or three (20 dpf) fish per replicate. Scale bar: 500 μm.
https://doi.org/10.1371/journal.pone.0199737.g002
Table 1. Tumorigenesis incidence of Gfap fish after crossing with Tp53 mutant.
# of generated fish # of fish with tumor
(over 1 year post fertilization)
Incidence of non-CNS-tumors (%) Incidence of CNS-tumors (%)
GfapGFP 35 3 8.6 0
GfapR132C 30 3 10 0
GfapG70D 28 4 14.3 0
Gfapwt 15 1 6 0
Heterozygous Tp53 mutant 13 2 15 0
https://doi.org/10.1371/journal.pone.0199737.t001
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signs of collagen maturation defects or brain hemorrhage, which may provide an explanation
why our fish are able to survive into adulthood. The absence of collagen maturation defects in
our fish may be related to the level of D2HG accumulation in our model system, the expression
level of IDH1R132H in our transgenic fish, and/or to the more limited temporal expression of
our constructs. D2HG accumulation may also be limited as it is likely able to diffuse out of the
fish into the water of the tank. This may explain that only a modest increase in the D2HG level
was detected in the IDH1-mutated fish. We failed to detect changes in 5hmc levels in the
IDH1-mutated embryos which may also be caused by insufficient accumulation of local
D2HG within the fish. In addition, any potential effects on fish ‘fitness’ is selected against in
the process of generating transgenic lines: only healthy fish (despite elevated D2HG levels) are
used to generate stable lines.
We were unable to detect CNS-specific tumors in our transgenic zebrafish lines. This is in
line with data from mouse models in which brain tumors were thus far not detected. This sup-
ports the notion that IDH1 mutation alone may be insufficient to promote tumor formation
and other genetic alterations are required [40]. In most astrocytomas, TP53 and IDH muta-
tions often co-occur [41]. However, the combination of IDH1 and tp53 mutations did not
induce gliomas in our zebrafish model. Similarly, IDH1 mutations also did not increase tumor
incidence in Tp53 mutant mouse model, despite the observation that IDH1 mutations induce
pre-cancerous lesions such as proliferative subventricular nodules in one mouse model, but
interestingly not in an almost identical other model [23, 25]. Similarly, mutations in IDH1/2 in
combination with Tp53 deficiency were insufficient to induce gliomagenesis in RCAS/tva
mouse models [40]. Since mutations in IDH and TP53 are the most common genetic alterations
Fig 3. Treatment of transgenic zebrafish with 10μM IDH1 mutant inhibitor, AGI-5198, resulted in a reduction in the
D2HG level in the IDH1 mutant zebrafish. D2HG level in NesR132H transgenic zebrafish was reduced to 41% of untreated
(A). D2HG level in GfapR132H transgenic zebrafish was reduced to 25% of untreated (B) The L2HG level was not affected by
AGI-5198 (C and D). D2HG and L2HG measurements were averages of two replicates using five fish per replicate.
https://doi.org/10.1371/journal.pone.0199737.g003
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in astrocytomas, it remains unclear which additional mutations are required to induce glioma
formation in our zebrafish model. Candidate genes should include oncogenic drivers ATRX
and/or PDGFRA as they are present at significant frequency in lower grade gliomas. Of note,
zebrafish has been appreciated as a valid model to study tumorigenesis, for example, tp53-
mutant fish develop schwannomas and gliomas can also be generated in zebrafish by activating
akt1 alone [42]. Our data also show that D2HG can be present at high levels throughout the
development of zebrafish without any overt signs of pathology (although a minority of our
transgenic fish did show defects in tail development). These data are in line with the observation
that some D2HG aciduria patients, which have high levels of D2HG due to mutations in IDH2
or D2HGDH, do not have any overt phenotype. Moreover, D2HG aciduria patients do not have
an increased incidence of brain tumors [43].
In conclusion, we developed various transgenic zebrafish models with CNS-specific expres-
sion of IDH1 mutation. We identified tail defects in a subset of IDH1-mutant fish, but we
thus-far failed to identify tumors. Nevertheless, our transgenic zebrafish are a suitable model
to functionally study the IDH1 mutation in vivo or to use as a drug screening model.
Supporting information
S1 Fig. Fluorescent imaging showed expression of transgene in the central nervous system
of Nestin (A) and Gfap (B) transgenic zebrafish lines on 1, 3 and 5 dpf. White arrow head:
CNS-specific GFP. Yellow arrow head: auto fluorescence in the yolk sac.
(TIF)
S2 Fig. Immunohistochemistry using anti-IDH1R132H antibody demonstrated expression
of IDH1R132H specific expression in Nestin zebrafish but not in IDH1wt transgenic fish.
(TIF)
S3 Fig. D2HG measurement in NesIDH1wt and NesR132H transgenic fish. No differences in
D2HG levels between macro-dissected and whole embryos were observed.
(TIF)
S4 Fig. 5hmC levels was not affected by high levels of D2HG in transgenic Nes R132H mutant
zebrafish. A. 5hmC levels in NesIDH1wt, Nes R132H and non-transgenic zebrafish embryos were
measured using slotblot stained with an 5hmC antibody (quantification of bands on the right
panel). Similar results were obtained in three independent experiments one of which is shown
below. B. Representative images showing 5-hmC immunostaining in NesIDH1wt, Nes R132H
transgenic and non-transgenic zebrafish embryo slices at 3dpf. NT: non-transgenic zebrafish.
(TIF)
S5 Fig. Collagen maturation was not affected in NesR132H mutant zebrafish. Top half of the
blot was stained for type IV Collagen, bottom half was stained for Tubulin (as loading control).
Similar data were obtained in three independent experiments. NT: non-transgenic zebrafish.
H: head of zebrafish embryos. W: whole embryo.
(TIF)
S6 Fig. NesR132H transgenic zebrafish with CNS-accumulation of D2HG showed no gross
histological abnormalities on 3dpf on H&E staining.
(TIF)
S7 Fig. Gata2GFP transgenic zebrafish shows expression in the notochord of zebrafish.
Yellow arrow: In Gata2IDHwt transgenic fish the transgene is expressed in non-CNS regions
(yellow arrow) whereas GfapIDH1wt transgenic fish show CNS-specific expression of
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transgene (white arrow). The blue arrow shows an absence of GFP signal in non-transgenic
fish.
(TIF)
S8 Fig. Direct injection of fertilized zebrafish embryos with Gfap constructs showed
mutant-specific tail defects. Fluorescent imaging showed CNS-specific expression of injected
construct GfapGFP (A), GfapIDH1wt (B) and GfapR132C(C) and the corresponding bright-field
images (A’-C’). D: the percentage of GFP-positive embryos with tail defects per construct. The
ratio of injected embryos with tail defect were calculated based on results of three independent
experiments (~100 eggs/construct/experiment). n.s: non-significant. Scale bar: 500μm.
(TIF)
S9 Fig. An example of a schwannoma in tp53 deficient transgenic zebrafish crossed with
IDH1 transgenic fish. Euthanized 1-year old fish with a distended abdominal cavity (A). Fish
were fixed in paraffin blocks (B) and sectioned slides were stained with hematoxylin/eosin for
histological examination (C). D and E: enlarged images of sections in C, histological feature of
tumors were consistent with the schwannomas as previously demonstrated (36).
(TIF)
S10 Fig. Dose-response analysis of AGI-5198 on Nestin transgenic zebrafish. Maximal inhi-
bition is reached at 10μM.
(TIF)
S1 Table. Primers used for the examination of IDH1 expression levels in zebrafish by
QPCR.
(PDF)
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